Dosimetric Predictors of Dysphonia after Intensity-modulated Radiotherapy for Oropharyngeal Carcinoma

G. Sanguineti, F. Ricchetti, T. McNutt, B. Wu, C. Fiorino

Research output: Contribution to journalArticle

Abstract

Aims: To investigate dosimetric predictors of voice changes after whole-field intensity-modulated radiotherapy (IMRT). Materials and methods: Patients treated with whole-field IMRT for oropharyngeal/unknown primary tumours were selected for the present retrospective study having grossly uninvolved larynx at the time of radiotherapy and at least one follow-up visit. Voice changes were prospectively scored at each follow-up examination according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 scale and self-reported by two items (HN4 and HN10) of the Functional Assessment of Cancer Therapy-Head and Neck Scale (FACT-HN) questionnaire. Predictors of toxicity were investigated at logistic regression, including various patient and tumour characteristics, as well as individual dosimetric data. Results: With a median follow-up of 18 months (range 3-46 months), peak CTCAE dysphonia was graded as 2 in 13 patients (10.5%), whereas 45 patients (36.3%) reported peak grade 0-1 voice changes according to FACT-HN4. Communication (FACT-HN10) was barely affected. At multivariate analysis, the mean laryngeal dose was an independent predictor of both grade 2 CTCAE dysphonia (odds ratio=1.10, 95% confidence interval 1.01-1.20, P=0.025) and grade 0-1 FACT-HN4 voice changes (odds ratio=1.11, 95% confidence interval 1.04-1.18, P=0.001). Further stratification optimised by a receiver operating characteristic (ROC) analysis showed that, to minimise the risk of grade 0-1 FACT-HN4 voice changes, the mean dose to the larynx has to be kept ≤49.4Gy. Conclusion: Voice changes after whole-field IMRT are common, but mild, and are strictly correlated to the dose received by the uninvolved larynx; in order to minimise the risk of side-effects, the mean dose to the larynx should be kept ≤50Gy.

Original languageEnglish
Pages (from-to)32-38
Number of pages7
JournalClinical Oncology
Volume26
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Dysphonia
Intensity-Modulated Radiotherapy
Larynx
Carcinoma
Terminology
Unknown Primary Neoplasms
Odds Ratio
Confidence Intervals
Head and Neck Neoplasms
ROC Curve
Radiotherapy
Multivariate Analysis
Retrospective Studies
Logistic Models
Communication
Neoplasms

Keywords

  • Dosimetric predictors
  • Radiotherapy
  • Voice changes

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Dosimetric Predictors of Dysphonia after Intensity-modulated Radiotherapy for Oropharyngeal Carcinoma. / Sanguineti, G.; Ricchetti, F.; McNutt, T.; Wu, B.; Fiorino, C.

In: Clinical Oncology, Vol. 26, No. 1, 01.2014, p. 32-38.

Research output: Contribution to journalArticle

@article{53c56d04cbe643458d70cfa913f2b339,
title = "Dosimetric Predictors of Dysphonia after Intensity-modulated Radiotherapy for Oropharyngeal Carcinoma",
abstract = "Aims: To investigate dosimetric predictors of voice changes after whole-field intensity-modulated radiotherapy (IMRT). Materials and methods: Patients treated with whole-field IMRT for oropharyngeal/unknown primary tumours were selected for the present retrospective study having grossly uninvolved larynx at the time of radiotherapy and at least one follow-up visit. Voice changes were prospectively scored at each follow-up examination according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 scale and self-reported by two items (HN4 and HN10) of the Functional Assessment of Cancer Therapy-Head and Neck Scale (FACT-HN) questionnaire. Predictors of toxicity were investigated at logistic regression, including various patient and tumour characteristics, as well as individual dosimetric data. Results: With a median follow-up of 18 months (range 3-46 months), peak CTCAE dysphonia was graded as 2 in 13 patients (10.5{\%}), whereas 45 patients (36.3{\%}) reported peak grade 0-1 voice changes according to FACT-HN4. Communication (FACT-HN10) was barely affected. At multivariate analysis, the mean laryngeal dose was an independent predictor of both grade 2 CTCAE dysphonia (odds ratio=1.10, 95{\%} confidence interval 1.01-1.20, P=0.025) and grade 0-1 FACT-HN4 voice changes (odds ratio=1.11, 95{\%} confidence interval 1.04-1.18, P=0.001). Further stratification optimised by a receiver operating characteristic (ROC) analysis showed that, to minimise the risk of grade 0-1 FACT-HN4 voice changes, the mean dose to the larynx has to be kept ≤49.4Gy. Conclusion: Voice changes after whole-field IMRT are common, but mild, and are strictly correlated to the dose received by the uninvolved larynx; in order to minimise the risk of side-effects, the mean dose to the larynx should be kept ≤50Gy.",
keywords = "Dosimetric predictors, Radiotherapy, Voice changes",
author = "G. Sanguineti and F. Ricchetti and T. McNutt and B. Wu and C. Fiorino",
year = "2014",
month = "1",
doi = "10.1016/j.clon.2013.08.006",
language = "English",
volume = "26",
pages = "32--38",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Dosimetric Predictors of Dysphonia after Intensity-modulated Radiotherapy for Oropharyngeal Carcinoma

AU - Sanguineti, G.

AU - Ricchetti, F.

AU - McNutt, T.

AU - Wu, B.

AU - Fiorino, C.

PY - 2014/1

Y1 - 2014/1

N2 - Aims: To investigate dosimetric predictors of voice changes after whole-field intensity-modulated radiotherapy (IMRT). Materials and methods: Patients treated with whole-field IMRT for oropharyngeal/unknown primary tumours were selected for the present retrospective study having grossly uninvolved larynx at the time of radiotherapy and at least one follow-up visit. Voice changes were prospectively scored at each follow-up examination according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 scale and self-reported by two items (HN4 and HN10) of the Functional Assessment of Cancer Therapy-Head and Neck Scale (FACT-HN) questionnaire. Predictors of toxicity were investigated at logistic regression, including various patient and tumour characteristics, as well as individual dosimetric data. Results: With a median follow-up of 18 months (range 3-46 months), peak CTCAE dysphonia was graded as 2 in 13 patients (10.5%), whereas 45 patients (36.3%) reported peak grade 0-1 voice changes according to FACT-HN4. Communication (FACT-HN10) was barely affected. At multivariate analysis, the mean laryngeal dose was an independent predictor of both grade 2 CTCAE dysphonia (odds ratio=1.10, 95% confidence interval 1.01-1.20, P=0.025) and grade 0-1 FACT-HN4 voice changes (odds ratio=1.11, 95% confidence interval 1.04-1.18, P=0.001). Further stratification optimised by a receiver operating characteristic (ROC) analysis showed that, to minimise the risk of grade 0-1 FACT-HN4 voice changes, the mean dose to the larynx has to be kept ≤49.4Gy. Conclusion: Voice changes after whole-field IMRT are common, but mild, and are strictly correlated to the dose received by the uninvolved larynx; in order to minimise the risk of side-effects, the mean dose to the larynx should be kept ≤50Gy.

AB - Aims: To investigate dosimetric predictors of voice changes after whole-field intensity-modulated radiotherapy (IMRT). Materials and methods: Patients treated with whole-field IMRT for oropharyngeal/unknown primary tumours were selected for the present retrospective study having grossly uninvolved larynx at the time of radiotherapy and at least one follow-up visit. Voice changes were prospectively scored at each follow-up examination according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 scale and self-reported by two items (HN4 and HN10) of the Functional Assessment of Cancer Therapy-Head and Neck Scale (FACT-HN) questionnaire. Predictors of toxicity were investigated at logistic regression, including various patient and tumour characteristics, as well as individual dosimetric data. Results: With a median follow-up of 18 months (range 3-46 months), peak CTCAE dysphonia was graded as 2 in 13 patients (10.5%), whereas 45 patients (36.3%) reported peak grade 0-1 voice changes according to FACT-HN4. Communication (FACT-HN10) was barely affected. At multivariate analysis, the mean laryngeal dose was an independent predictor of both grade 2 CTCAE dysphonia (odds ratio=1.10, 95% confidence interval 1.01-1.20, P=0.025) and grade 0-1 FACT-HN4 voice changes (odds ratio=1.11, 95% confidence interval 1.04-1.18, P=0.001). Further stratification optimised by a receiver operating characteristic (ROC) analysis showed that, to minimise the risk of grade 0-1 FACT-HN4 voice changes, the mean dose to the larynx has to be kept ≤49.4Gy. Conclusion: Voice changes after whole-field IMRT are common, but mild, and are strictly correlated to the dose received by the uninvolved larynx; in order to minimise the risk of side-effects, the mean dose to the larynx should be kept ≤50Gy.

KW - Dosimetric predictors

KW - Radiotherapy

KW - Voice changes

UR - http://www.scopus.com/inward/record.url?scp=84890792966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890792966&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2013.08.006

DO - 10.1016/j.clon.2013.08.006

M3 - Article

C2 - 23992739

AN - SCOPUS:84890792966

VL - 26

SP - 32

EP - 38

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 1

ER -